Skip to content

Bone Healing Accelerant (BHA) Versus Autologous Bone Grafting (ABG) for Hindfoot or Ankle Arthrodesis

A Multicenter, Randomized, Controlled, Blinded Study of the Safety and Efficacy of Bone Healing Accelerant Versus Autologous Bone Grafting in Subjects Undergoing Hindfoot or Ankle Arthrodesis and Who Require Supplementary Grafting

Status
Withdrawn
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06258499
Enrollment
0
Registered
2024-02-14
Start date
2024-03-31
Completion date
2024-11-30
Last updated
2024-02-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Foot Deformities

Brief summary

This study is being conducted to demonstrate the safety and effectiveness of Bone Healing Accelerant (BHA) product when applied to the joint space of the ankle of hindfoot (the section of the foot immediately below the ankle joint) during fusion surgery. It is hypothesized that by 6 months, the number of subjects with successful bone fusion will be greater in the BHA-treated group compared to subjects treated with standard of care alone.

Interventions

COMBINATION_PRODUCTBHA

BHA active ingredients include a blood-derived component and beta-tricalcium phosphate. It is manually placed into the joint fusion space during fusion surgery.

Sponsors

Carmell Therapeutics Corporation
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patient has pain with weight-bearing in the joint(s) below that, in the opinion of the Investigator, warrants arthrodesis: 1. Tibiotalar (ankle) 2. Talocalcaneal (subtalar) 3. Talonavicular 4. Calcaneocuboid 5. Double hindfoot (e.g., talonavicular and talocalcaneal joints) 6. Triple hindfoot (subtalar, talonavicular and calcaneocuboid joints * Joint space(s) can, in the opinion of the Investigator, be adequately filled with no more than 9 cc of graft material (BHA or ABG) * Each fused joint can be adequately compressed and rigidly stabilized with plates, screws, staples or a combination thereof. External fixation, percutaneous Kirschner wires or intramedullary rods may not be used. * Patient is willing and able to comply with all study requirements including all postoperative clinical and radiographic evaluations. * If patient is a woman of childbearing bearing potential (not post-menopausal for 12 months or surgically sterile), patient has a urine pregnancy test with a negative result at screening and on the day of surgery, prior to the procedure. These trial participants must commit to adequate birth control through the 52-week follow-up

Exclusion criteria

* Skeletally immature patients (i.e., radiographic evidence of open physes), regardless of age * Bone deficit, defect or void requiring a structural graft * Condition requiring intramedullary nailing or external fixation for the arthrodesis * Condition requiring osteotomy or fusion of any midfoot joints. * Prior arthroplasty, arthrodesis, major surgical repair or reconstruction of the index ankle or hindfoot joints.

Design outcomes

Primary

MeasureTime frameDescription
Successful Radiographic Fusion24 weeksGreater than or equal to 50% bone bridging across joint space for the full complement of joints fused as determined by CT in the absence of secondary surgical or nonsurgical interventions intended to promote fusion.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026